COST EFFECTIVENESS OF DIFFERENT TARGETED TREATMENT SEQUENCES FOR HER2-POSITIVE METASTATIC BREAST CANCER

被引：0
|
作者：
Diaby, V [1 ]
Adunlin, G. [2 ]
Ali, A. [1 ]
Zeichner, S. [3 ]
Lopes, G. [4 ]
Kohn, C. G. [5 ]
Montero, A. J. [6 ]
机构：
[1] Florida A&M Univ, Tallahassee, FL 32307 USA
[2] Virginia Commonwealth Univ, Richmond, VA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Hosp Coracao & Oncoclin Brasil Grp, Sao Paulo, Brazil
[5] Univ St Joseph, Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1592
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN93
引用
收藏
页码：A150 / A150
页数：1
相关论文
共 50 条
  • [41] Emerging Targeted Therapies for HER2-Positive Breast Cancer
    Florencia Mercogliano, Maria
    Bruni, Sofia
    Luciana Mauro, Florencia
    Schillaci, Roxana
    CANCERS, 2023, 15 (07)
  • [42] Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews
    Diaby, Vakaramoko
    Almutairi, Reem D.
    Babcock, Aram
    Moussa, Richard K.
    Ali, Askal
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 353 - 364
  • [43] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [44] HER2-positive metastatic breast cancer: A changing scenario
    Mustacchi, G.
    Biganzoli, L.
    Pronzato, P.
    Montemurro, F.
    Dambrosio, M.
    Minelli, M.
    Molteni, L.
    Scaltriti, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (01) : 78 - 87
  • [45] Therapy for HER2-Positive Metastatic Breast Cancer REPLY
    Winer, Eric P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [46] Overcoming resistance in Her2-positive metastatic breast cancer
    Oksuzoglu, Omur Berna
    LEUKEMIA RESEARCH, 2018, 73 : S13 - S13
  • [47] HER2-Positive Metastatic Breast Cancer: A Comprehensive Review
    Exman, Pedro
    Tolaney, Sara M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 40 - 50
  • [48] Advancing outcomes of metastatic HER2-positive breast cancer
    Chumsri, Saranya
    LANCET, 2023, 401 (10390): : 1746 - 1747
  • [49] HER2-targeted Therapeutic Strategies for HER2-positive Metastatic Breast Cancers
    Fujii, Teruhiko
    Miwa, Keisuke
    Ushijima, Tomoyuki
    Matsunaga, Mototsugu
    Fukahori, Masaru
    Yuge, Kotaro
    Toh, Uhi
    Iwakuma, Nobutaka
    Takahashi, Ryuji
    Takahashi, Hiroki
    Takenaka, Miki
    Mishima, Mai
    Akagi, Yoshito
    Kage, Masayoshi
    Nakagawa, Shino
    CURRENT CANCER THERAPY REVIEWS, 2014, 10 (03) : 225 - 233
  • [50] Optimizing the Management of Metastatic HER2-Positive Breast Cancer
    Goel S.
    Tolaney S.
    Current Breast Cancer Reports, 2015, 7 (4) : 190 - 202
12345